Table 1 Patients’ clinical and histopathological characteristics (n = 68)
From: CD146 as an adverse prognostic factor in uterine sarcoma
Characteristics | No. case | LMS (n = 36) | ESS (n = 25) | MMMT (n = 7) |
|---|---|---|---|---|
Age (years) | ||||
<50 | 38 (55.8 %) | 20 | 17 | 1 |
≥50 | 30 (44.2 %) | 16 | 8 | 6 |
Stage | ||||
I | 36 (53.9 %) | 19 | 13 | 4 |
II | 3 (4.4 %) | 3 | 0 | 0 |
III | 22 (32.4 %) | 7 | 12 | 3 |
IV | 7 (10.3 %) | 7 | 0 | 0 |
Tumor size (cm) | ||||
<5 | 30 (44.1 %) | 16 | 11 | 3 |
≥5 | 38 (55.9 %) | 20 | 14 | 4 |
Pelvic lymphadenectomy | ||||
Yes | 34 (50 %) | 17 | 13 | 4 |
No | 34 (50 %) | 19 | 12 | 3 |
Lymph node metastasis | ||||
Positive | 24 (35.3 %) | 18 | 4 | 2 |
Negative | 44 (64.7 %) | 33 | 9 | 2 |
Surgical procedure | ||||
TAH ± BSO/OT/PL/PLND | 8 (11.8 %) | 4 | 4 | 0 |
TAH + BSO ±/PL/OT | 29 (42.6 %) | 17 | 12 | 0 |
TAH + BSO + PL ± OT ± PLND | 31 (45.6 %) | 15 | 9 | 7 |
Chemotherapy | 22 (32.4 %) | 13 | 9 | 0 |
Radiotherapy | 4 (5.9 %) | 1 | 3 | 0 |
Hormone therapy | 1 (1.5 %) | 0 | 1 | 0 |
Chemotherapy and radiotherapy | 20 (29.4 %) | 10 | 3 | 7 |
Chemotherapy and hormone therapy | 3 (4.4 %) | 1 | 2 | 0 |
Radiotherapy and hormone therapy | 1 (1.5 %) | 0 | 1 | 0 |
No adjuvant therapy | 17 (25 %) | 11 | 6 | 0 |
Distant metastasis and recurrence | ||||
Pelvic | 10 (14.7 %) | 6 | 3 | 1 |
Pelvic and liver/lung | 6 (8.8 %) | 4 | 2 | 0 |
Lung | 4 (5.9 %) | 3 | 1 | 0 |
Other parts | 6 (8.8 %) | 5 | 1 | 0 |
None | 42 (61.5 %) | 18 | 18 | 6 |